Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non–ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.

MLA

Farhan, Serdar, et al. “Fasting Glucose, NT-ProBNP, Treatment with Eptifibatide, and Outcomes in Non–ST-Segment Elevation Acute Coronary Syndromes: An Analysis from EARLY ACS.” International Journal of Cardiology, vol. 232, Apr. 2017, pp. 264–70. EBSCOhost, https://doi.org/10.1016/j.ijcard.2017.01.007.

APA

Farhan, S., Clare, R. M., Jarai, R., Giugliano, R. P., Lokhnygina, Y., Harrington, R. A., Kristin Newby, L., & Huber, K. (2017). Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non–ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. International Journal of Cardiology, 232, 264–270. https://doi.org/10.1016/j.ijcard.2017.01.007

Chicago

Farhan, Serdar, Robert M. Clare, Rudolf Jarai, Robert P. Giugliano, Yuliya Lokhnygina, Robert A. Harrington, L. Kristin Newby, and Kurt Huber. 2017. “Fasting Glucose, NT-ProBNP, Treatment with Eptifibatide, and Outcomes in Non–ST-Segment Elevation Acute Coronary Syndromes: An Analysis from EARLY ACS.” International Journal of Cardiology 232 (April): 264–70. doi:10.1016/j.ijcard.2017.01.007.